SAGE Quote, Financials, Valuation and Earnings

Akero Therapeutics has a net margin of -747.33% compared to Sage Therapeutics's net margin of --. Sage Therapeutics's return on equity of -63.59% beat Akero Therapeutics's return on equity of --.

Sage Therapeutics has a consensus price target of $8.10, signalling upside risk potential of 4%. On the other hand Akero Therapeutics has an analysts' consensus of $77.64 which suggests that it could grow by 89.36%. Given that Akero Therapeutics has higher upside potential than Sage Therapeutics, analysts believe Akero Therapeutics is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.477, which suggesting that the stock is 52.304% less volatile than S&P 500. In comparison Akero Therapeutics has a beta of -0.174, suggesting its less volatile than the S&P 500 by 117.392%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Akero Therapeutics pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $12.8M, which are larger than Akero Therapeutics quarterly revenues of --. Sage Therapeutics's net income of -$95.8M is lower than Akero Therapeutics's net income of -$70M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Akero Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 11.48x versus -- for Akero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Biogen has a net margin of -747.33% compared to Sage Therapeutics's net margin of 10.87%. Sage Therapeutics's return on equity of -63.59% beat Biogen's return on equity of 10.33%.

Sage Therapeutics has a consensus price target of $8.10, signalling upside risk potential of 4%. On the other hand Biogen has an analysts' consensus of $190.50 which suggests that it could grow by 60.3%. Given that Biogen has higher upside potential than Sage Therapeutics, analysts believe Biogen is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.477, which suggesting that the stock is 52.304% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $12.8M, which are smaller than Biogen quarterly revenues of $2.5B. Sage Therapeutics's net income of -$95.8M is lower than Biogen's net income of $266.7M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Biogen's PE ratio is 10.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 11.48x versus 1.79x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Cytokinetics has a net margin of -747.33% compared to Sage Therapeutics's net margin of -886.28%. Sage Therapeutics's return on equity of -63.59% beat Cytokinetics's return on equity of --.

Sage Therapeutics has a consensus price target of $8.10, signalling upside risk potential of 4%. On the other hand Cytokinetics has an analysts' consensus of $77.19 which suggests that it could grow by 90.92%. Given that Cytokinetics has higher upside potential than Sage Therapeutics, analysts believe Cytokinetics is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.477, which suggesting that the stock is 52.304% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.231%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $12.8M, which are smaller than Cytokinetics quarterly revenues of $16.9M. Sage Therapeutics's net income of -$95.8M is higher than Cytokinetics's net income of -$150M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 11.48x versus 244.55x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -747.33% compared to Sage Therapeutics's net margin of --. Sage Therapeutics's return on equity of -63.59% beat Viking Therapeutics's return on equity of --.

Sage Therapeutics has a consensus price target of $8.10, signalling upside risk potential of 4%. On the other hand Viking Therapeutics has an analysts' consensus of $89.50 which suggests that it could grow by 258.14%. Given that Viking Therapeutics has higher upside potential than Sage Therapeutics, analysts believe Viking Therapeutics is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.477, which suggesting that the stock is 52.304% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.838, suggesting its less volatile than the S&P 500 by 16.205%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $12.8M, which are larger than Viking Therapeutics quarterly revenues of --. Sage Therapeutics's net income of -$95.8M is lower than Viking Therapeutics's net income of -$45.6M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 11.48x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.